Document Classification

Section Type: RESULTS

Text: Our main findings were i) compared to placebo, rosiglitazone significantly decreased the plasma levels of the naturally occurring interleukin (IL) 1 inhibitor, IL1 receptor antagonist (IL1Ra ; P = 0. 001), potentially reflecting inflammatory effects on the IL1 system ; ii) parallel to this, rosiglitazone decreased plasma levels of IL10 (P = 0. 029) further suggesting inflammatory effects ; iii) rosiglitazone decreased uric acid levels (P = 0. 001), and monocyte chemoattractant protein-1 (P = 0. 05) and C-reactive protein (P = 0. 06) tended to be lower after rosiglitazone than placebo, suggesting potential pro- and anti-inflammatory effects simultaneously and iv) in vitro, rosiglitazone enhanced IL1Ra and decreased IL1beta in THP-1 monocytes, illustrating the complex effects of these medications, potentially exhibiting anti-inflammatory effects on the IL1 system in certain tissues or cells at least at certain concentrations.